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Abstract
Background: Mounting evidence supports a physiological role for silicon (Si) as orthosilicic acid (OSA, Si(OH)4)
in bone formation. The effect of oral choline-stabilized orthosilicic acid (ch-OSA) on markers of bone turnover
and bone mineral density (BMD) was investigated in a double-blind placebo-controlled trial.
Methods: Over 12-months, 136 women out of 184 randomized (T-score spine < -1.5) completed the study and
received, daily, 1000 mg Ca and 20 μg cholecalciferol (Vit D3) and three different ch-OSA doses (3, 6 and 12 mg
Si) or placebo. Bone formation markers in serum and urinary resorption markers were measured at baseline, and
after 6 and 12 months. Femoral and lumbar BMD were measured at baseline and after 12 months by DEXA.
Results: Overall, there was a trend for ch-OSA to confer some additional benefit to Ca and Vit D3 treatment,
especially for markers of bone formation, but only the marker for type I collagen formation (PINP) was significant
at 12 months for the 6 and 12 mg Si dose (vs. placebo) without a clear dose response effect. A trend for a dose-
corresponding increase was observed in the bone resorption marker, collagen type I C-terminal telopeptide
(CTX-I).
Lumbar spine BMD did not change significantly. Post-hoc subgroup analysis (baseline T-score femur < -1) however
was significant for the 6 mg dose at the femoral neck (T-test). There were no ch-OSA related adverse events
observed and biochemical safety parameters remained within the normal range.
Conclusion: Combined therapy of ch-OSA and Ca/Vit D3 had a potential beneficial effect on bone collagen
compared to Ca/Vit D3 alone which suggests that this treatment is of potential use in osteoporosis. NTR 1029
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Osteoporosis has become a leading cause of morbidity
and mortality worldwide and is an ever-increasing drain
on healthcare resources. Osteoporosis is defined as pro-
gressive skeletal disorder, characterised by low bone mass
(osteopenia) and micro-architectural deterioration,
resulting in an increase in bone fragility and increased risk
to factures [1]. The aetiology of osteoporosis is multifacto-
rial [2,3] with influences from genetics, endocrine func-
tion, exercise and nutrition [4]. The primary cause for the
decline in bone mineral density (BMD) and increased sus-
ceptibility to fracture in women, is the decrease in circulat-
ing estrogens at the onset of menopause.
With hormone replacement therapy's diminishing popu-
larity [5,6] there is a clinical need for alternative well-tol-
erated pharmacological or nutritional treatments that can
safely be used soon after the menopause and which effec-
tively prevent bone loss and the development of oste-
oporosis [7]. In this regard several studies have looked at
the role of bone minerals (magnesium [8] and fluoride
[9,10]) and nutritional trace elements (zinc [11,12], cop-
per [11], manganese [13]) including silicon, in bone
homeostasis. Experimental silicon deprivation in rats [14-
16] and chicks [17,18] demonstrated marked effects on
growth and bone metabolism which in some studies
resulted in aberrant connective tissue and bone minerali-
zation (thinner cortex, less calcified bone matrix) and
bone defects. Keeting [19] and Schütze [20] reported that
the silicon-containing compound zeolite (sodium zeolite
A) stimulates DNA synthesis in osteoblasts and inhibits
osteoclast-mediated bone resorption in vitro. Further-
more, in 1992 Mourkarzel [21] reported that a decreased
serum Si concentration in total parenterally fed infants
was associated with a decreased bone mineral content
compared to healthy controls. This was the first observa-
tion of a possible dietary silicon deficiency in humans. Sil-
icon supplementation, on the other hand, was shown to
have beneficial effects on bone. In a small intervention
study [22] treatment of osteoporotic subjects with silicon
in the form of monomethyltrisilanol increased trabecular
bone volume compared to non-treated controls. In
another open intervention study [23] femoral density was
significantly increased after intramuscular administration
of silicon (50 mg), again, as monometyltrisilanol twice a
week for 4 months. An epidemiological study reported a
positive correlation between dietary Si intake and bone
mineral density at the hip in men and pre-menopausal
women, suggesting that a higher Si intake may have a ben-
eficial effect on cortical bone health [24]. More recently
the same research group [25] demonstrated that dietary
silicon intake is positively associated with BMD in post-
menopausal women taking hormone replacement ther-
apy (HRT), suggesting a possible interaction between
estrogen status and effects of silicon on bone.
Orthosilicic acid (OSA), also known as soluble silica, is
present in low concentrations (< 10-3 M) in beverages and
water. Dietary silicates undergo hydrolysis, forming OSA
that is readily absorbed in the gastrointestinal tract [26].
Physiological concentrations of OSA were recently found
to stimulate collagen type I synthesis and osteoblastic dif-
ferentiation in human osteoblast-like cells in vitro [27].
Supplementation of young animals with a specific
choline-stabilized orthosilicic acid complex (ch-OSA), a
concentrated and stabilized source of OSA, resulted in a
higher collagen concentration in the skin [28] and an
increased femoral bone density [29]. Treatment of
humans with oral ch-OSA for 20 weeks, resulted in a sig-
nificant positive effect on skin surface and skin mechani-
cal properties [30], suggesting a regeneration or de novo
synthesis of collagen fibers. Furthermore, Calomme et al.
investigated the effect of ch-OSA supplementation (30
weeks) on bone loss in aged ovariectomized (OVX) rats
[31]. The increase in bone turnover in OVX rats tended to
be reduced by ch-OSA supplementation. BMD was signif-
icantly increased at two sites in the distal femur in OVX
rats supplemented with ch-OSA compared to OVX con-
trols. This study demonstrated that ch-OSA supplementa-
tion partially prevents femoral bone loss in the aged OVX
rat model.
Considering the suggested role of silicon in bone mineral-
ization, ch-OSA may be useful as a preventive or therapeu-
tic agent against osteoporosis in combination with
calcium and vitamin D. In the present trial we evaluated
the effect of oral choline-stabilized orthosilicic acid on
markers of bone turnover and on bone mineral density in
osteopenic women.
Methods
Subjects
184 osteopenic, but otherwise healthy, Caucasian women
with a T-score < -1.5 at the lumbar spine by DEXA scan
were recruited by local advertising in St Thomas' Hospital,
London. Screening occurred over approximately 24
months and the study was conducted between June 2001
and February 2004. The study protocol was approved by
St. Thomas' Hospital Local Research Ethics Committee
and all the women gave written informed consent prior to
commencing the study. Patients were excluded according
to the following criteria: renal failure as defined by serum
creatinine > 200 μmol/L, abnormal serum ferritin level
(normal range: 11–250 μg/L), concomitant medication
(treatment with phosphate-binding antacids > 6 months/
year), oral glucocorticoid treatment (> 8 months in the
previous year and > 7.5 mg/day prednisone equivalent, or
a total dose of more than 2 g prednisone equivalent in the
previous 12 months), local injectable glucocorticoid treat-
ment if > 5 injections per year, inhaled glucocorticoid
treatment if > 6 months in the previous year and morePage 2 of 10
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local topical administration were not excluded), concom-
itant or previous treatment for bone diseases (fluoride
salts: > 10 mg/day, for more than 2 weeks in the previous
12 months, biphosphanates: for more than 2 weeks in the
previous 12 months, oral estrogens, estradiol vaginal ring,
anti-estrogens, progesterones, anabolic steroids in the pre-
vious 3 months or used for more than 1 month in the pre-
vious 6 months, estradiol implants in the previous 3 years,
ipriflavone use in the previous 6 months or used for more
than 1 month in the previous 12 months, calcitonin use
in the previous month or used for more than 1 month in
the previous 6 months, other drugs for bone disease cur-
rently in development), concomitant and previous use of
food supplements containing silicon or horsetail herb
extract, bamboo extract, colloidal silicic acid, or silanol
derivatives in the previous 6 months.
All study methods and procedures were conducted in
accordance with the ethical standards of the Declaration
of Helsinki and Good Clinical Practice guidelines.
Study medication
Subjects who meet the inclusion and exclusion criteria
were randomly assigned to four groups to take by oral
route ch-OSA (Bio Minerals N.V., Belgium) or a placebo
(a choline-glycerol solution without ch-OSA but with
identical pH, colour and taste to ch-OSA; Bio Minerals
N.V., Belgium) daily for 12 months. Randomization of
patient number was performed by Bio Minerals n.v. with
GraphPad Software (GraphPad Software Inc., San Diego,
USA). Patients received a randomization number e.g.
from 001 to 184 in ascending order. Three different ch-
OSA doses (3, 6 and 12 drops) were used corresponding
to 3, 6, and 12 mg Si, which would increase dietary Si
intakes by 16.4, 33, and 66% in this age and gender group
[32]. The placebo group was divided in 3 subgroups (3, 6,
and 12 drops) to mimic the three different ch-OSA dos-
ages.
The study medication was delivered in sealed 30 ml plas-
tic bottles. The subjects were instructed to mix the ch-OSA
or placebo drops with 50 ml (2 floz, 1/4 glass) water or
juice and to consume immediately, preferably 30 minutes
before a meal or 2 hours after a meal. All subjects received
calcium and vitamin D3 (Calcichew/D3 forte, Shire, UK)
containing 1000 mg calcium and 20 μg cholecalciferol
daily.
The subjects returned their medication at each visit and
received new medication for a next study period of 3
months. Patient compliance was assessed at each visit by
quantifying the amount of study medication returned.
Patients and investigative site staff were blinded to group
assignment throughout the study (i.e. double-blinded).
Measurements
A basic clinical examination was performed at each visit
including measurement of body weight, height, systolic
and diastolic blood pressure and heart rate. Blood sam-
ples and single void urine samples were collected from
fasting subjects at baseline and after 12 months supple-
mentation to evaluate the safety parameters such as serum
glucose, urea, creatinine, uric acid, ferritin, total protein,
cholesterol, triglycerides, HDL-cholesterol, LDL-choles-
terol and total bilirubin, glutamic-oxalacetic transaminase
(GOT), glutamic-pyruvic transaminase (GPT), gamma-
glutamyltransferase (gamma-GT), cholinesterase, trypsin,
amylase, and lipase. Other serum parameters analysed
were sodium, potassium, calcium, phosphorus, copper,
magnesium, 25-OH-vit D3 and zinc. The following
parameters were analysed in urine: glucose, proteins,
ketones, bilirubin, urobilinogen blood, nitrite, leucocyte
esterase, pH, urea, uric acid, creatinine, sodium, potas-
sium, calcium, phosphorus and magnesium. All serum
and urine parameters were measured at baseline and after
12 months supplementation.
Bone mineral density (BMD) was assessed by Dual-Energy
X-ray Absorptiometry (DEXA) using a Hologic QDR 4500
W (Waltham, MA). Scans of the lumbar spine (L1 to L4)
and femur (neck, trochanter, intertrochanteric area,
Ward's triangle and total) were performed at screening
and/or at the inclusion visit and then after 12 months
treatment at the final visit. All measurements for identical
subjects were made on the same densitometer throughout
the study.
Biochemical markers of bone formation (osteocalcin
(OC), bone specific alkaline phosphatase (BAP), procolla-
gen type I N-terminal propeptide (PINP)) and bone
resorption (deoxypyridoline (DPD), C-terminal telopep-
tide of type I collagen (CTX-I)) were measured at baseline
and after 6 and 12 months of treatment. PINP was meas-
ured by competitive radio-immunoassay (Orion Diagnos-
tic PINP RIA kit) and osteocalcin by competitive ELISA
(Metra Osteocalcin EIA). BAP and DPD were measured by
a competitive immunoassay (Metra BAP EIA and Metra
DPD EIA, respectively). Urine CTX-I was measured using
the Nordic Bioscience Diagnostics™ serum CrossLaps®
ELISA assay kit (Denmark).
Statistical analysis
Results are expressed as means ± standard deviation (SD).
Outliers, defined as > (median+2SD) or < (median-2SD)
were omitted from bone marker analysis. Comparison of
multiple means was carried out by multiple covariate
analysis, adjusted for baseline values (bone markers,
BMD, MANCOVA). Differences between two groups (%
change from baseline) were evaluated with a t-test. Post-
hoc subgroup analysis was performed on a subpopulation
with osteopenia of the hip (T score < -1). All tests are two-Page 3 of 10
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a biological variation for bone markers of 35%, a group
size of 35 subjects per group/arm was calculated to
observe a significant difference (p < 0.05) in bone markers
of 25% between ch-OSA and placebo groups with a power
of 85%. A drop out rate of 20% was also taken into
account when determining the total number of patients
that had to be included (n = 175). Analysis was performed
using SPSS software (version 13.0, Chicago, USA).
Results
The study started with 184 mostly post-menopausal
(85%) women, mean age 60.7 ± 10.4 years, with docu-
mented osteopenia at the lumbar spine (T-score < -1.5), of
which 136 completed the study (37 in the placebo group
and 33 in each of the ch-OSA groups, see additional file 1
for more information). Baseline characteristics are repre-
sented in Table 1. There were no significant differences
between the groups, except that the 12 mg Si group had
statistically significant lower lumbar spine BMD (vs. 3 mg
Si group) and higher urinary DPD level (vs. placebo) at
baseline. The mean compliance (± SD) in the three ch-OSA
dosing groups was respectively 110% (± 40%, 3 mg Si in 3
drops), 110% (± 30%, 6 mg Si in 6 drops), and 101% (±
7%, 12 mg Si in 12 drops). The compliance in the placebo
groups was respectively 123% (± 13%, 3 drops), 107% (±
12%, 6 drops) and 100% (± 12%, 12 drops).
Safety and tolerability
Biochemical safety parameters were analysed in serum
(Table 2) and urine (Table 3) at baseline and after 12
months treatment. Forty-eight subjects did not complete
the study and reasons for withdrawal were medical or vol-
unteer decision (non-medical) i.e. volunteer changing
their mind as to taking further part in the study. Four cases
were classified as serious adverse events: neuro-endocrine
tumor combined with liver cancer (6 mg Si group), liver
cancer combined with gall bladder disease (6 mg Si
group), breast cancer (6 mg Si group), and cerebro-vascu-
lar accident (12 mg Si group). In three of these four cases
a disturbed liver function was observed at baseline, prior
to the start of the study. After considering the specific
pathology, these serious adverse events were reported as
not related to the study medication. No ch-OSA related
adverse events were observed.
Daily vitamin D3 supplementation significantly increased
(within the normal range) serum 25-OH-vit D3 in all
groups. Baseline values of total serum cholesterol and
LDL-cholesterol were higher than the upper limit of the
normal range in both the placebo and the three ch-OSA
dosing groups. The mean serum amylase concentration
was outside the normal range in the 3 mg Si group, both
at baseline and after 12 months treatment. Remaining
serum parameters were found within the normal range at
baseline and after 12 months treatment in all four groups.
Mean baseline urinary magnesium/creatinine ratio was
increased (outside normal range) in all four groups (Table
3). Baseline values of other parameters were within the
normal range in all groups and continued to be so after 12
months treatment.
Overall some significant differences between start and end
of treatment were noted in biochemical markers, but
these did not seem related to ch-OSA supplementation
(Tables 2 and 3) as, mainly, they occurred across all
groups including placebo, suggesting either Ca/vit D
related changes or choline-related changes.
Table 1: Baseline characteristics
Placebo ch-OSA
3 mg Si 6 mg Si 12 mg Si
AGE (years) 62.0 ± 10.9 (n = 37) 60.4 ± 11.8 (n = 33) 59.7 ± 9.4 (n = 33) 60.8 ± 9.7 (n = 33)
BMI 23.2 ± 3.0 (n = 37) 24.4 ± 3.8 (n = 33) 24.1 ± 4.6 (n = 33) 25.2 ± 3.8 (n = 33)
Menopausal status 6 pre/31 post (n = 37) 6 pre/27 post (n = 33) 5 pre/28 post (n = 33) 4 pre/29 post (n = 33)
BMD
Spine total (g/cm2) 0.797 ± 0.061 (n = 37) 0.805 ± 0.052 (n = 33) 0.805 ± 0.069 (n = 33) 0.776 ± 0.072b (n = 33)
Femur total (g/cm2) 0.789 ± 0.103 (n = 37) 0.791 ± 0.094 (n = 33) 0.792 ± 0.080 (n = 33) 0.781 ± 0.103 (n = 33)
Femur neck (g/cm2) 0.670 ± 0.085 (n = 37) 0.677 ± 0.085 (n = 33) 0.667 ± 0.079 (n = 33) 0.649 ± 0.084 (n = 33)
BONEMARKERS
OC (ng/ml) 9.74 ± 3.16 (n = 31) 10.17 ± 3.91 (n = 27) 10.65 ± 3.32 (n = 27) 10.16 ± 3.67 (n = 25)
BAP (U/L) 21.65 ± 6.30 (n = 32) 20.43 ± 7.24 (n = 26) 21.85 ± 6.31 (n = 27) 21.58 ± 7.36 (n = 27)
PINP (μg/L) 47.20 ± 13.45 (n = 30) 46.28 ± 21.46 (n = 26) 44.78 ± 16.07 (n = 28) 48.77 ± 15.09 (n = 30)
DPD (/Cr) 5.57 ± 3.12 (n = 28) 5.22 ± 1.50 (n = 26) 5.74 ± 1.45 (n = 27) 5.92 ± 1.57a (n = 28)
CTX-I (μg/mmol Cr) 359.01 ± 129.89 (n = 31) 331.88 ± 155.87 (n = 26) 349.10 ± 126.71 (n = 27) 360.43 ± 139.00 (n = 28)
Baseline characteristics of patients (n = 136), mean ± SD, a: p < 0.05 (unpaired t-test) versus placebo, b: p < 0.05 (unpaired t-test) versus 3 mg Si.Page 4 of 10
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Baseline bone markers levels were not significantly differ-
ent between the groups (Table 1), with the exception of
DPD, which was higher in the 12 mg Si group compared
to the placebo group (p < 0.05, t-test). In all groups, there
was a wide variation in bone marker levels after 6 and 12
months (Table 4). However, the variation or change in
levels (at 6 and 12 months) compared to baseline were
generally less with ch-OSA supplementation compared to
placebo (Table 4 & Figure 1); with a trend for a dose-
response in many cases (i.e., smallest change at the higher
dose). PINP levels were significantly higher after 12
months ch-OSA supplementation (6 and 12 mg Si/day)
compared to the placebo group (p < 0.05, MANCOVA;
Table 4). Furthermore, the change in PINP levels com-
pared to baseline levels were significantly smaller after 12
months ch-OSA supplementation (6 and 12 mg Si/day)
compared to the placebo group (p < 0.05, t-test; Figure 1).
A similar trend was observed for BAP reaching statistical
significance after 6 months ch-OSA supplementation (p <
0.05, t-test; Figure 1) for 3 and 12 mg Si/day.
Bone Mineral Density
Baseline BMD were comparable for all groups, however,
baseline BMD at the lumbar spine was significantly lower
in the 12 mg Si group compared to the low dose Si group
(3 mg Si/day) (p < 0.05, t-test, Table 1). BMD at the femur
and lumbar spine did not change significantly after 12
months ch-OSA administration (data not shown). Post-
hoc subgroup analysis of femoral neck BMD (baseline
femur T-score < -1) was significant at the 6 mg dose com-
pared to placebo which showed a negative change in BMD
(p < 0.05, t-test; Table 5).
Discussion
Well-tolerated pharmacological treatments that can effec-
tively prevent bone loss and the development of postmen-
opausal osteoporosis are needed. The efficacy of all
osteoporosis drug treatments is dependent on a sufficient
intake of calcium and vitamin D [3], as evidenced by the
fact that the pivotal studies underpinning the approval of
these drugs required adequate calcium and vitamin D
intake [33].
Table 2: Biochemical serum safety parameters
Normal 
range
Placebo (n = 37) ch-OSA
3 mg Si (n = 33) 6 mg Si (n = 33) 12 mg Si (n = 33)
LL UL Baseline T12 Baseline T12 Baseline T12 Baseline T12
Serology
Glucose (mg/dL) 70 110 87,43 ± 8,41 87,27 ± 6,74 89,03 ± 14,39 88,00 ± 10,32 86,50 ± 8,08 84,38 ± 9,23 86,16 ± 10,16 86,69 ± 9,72
Urea (mg/dL) 50,1 32,27 ± 8,66 32,39 ± 8,60 30,05 ± 8,51 32,46 ± 7,40 28,07 ± 7,45 30,33 ± 8,17(a) 31,71 ± 7,12 30,54 ± 5,93
Creatinine (mg/dL) 0,60 1,40 0,79 ± 0,13 0,83 ± 0,11(a) 0,76 ± 0,14 0,84 ± 0,13(a) 0,72 ± 0,12 0,79 ± 0,11(a) 0,80 ± 0,12 0,82 ± 0,09
Uric acid (mg/dL) 2,6 7,2 5,53 ± 1,07 5,52 ± 1,00 5,92 ± 1,38 6,23 ± 1,51 5,25 ± 1,07 5,09 ± 1,05 5,88 ± 1,01 5,71 ± 0,99
Ferritin (μg/L) 11 250 60,24 ± 38,75 52,38 ± 
33,81(a)
63,84 ± 37,24 59,72 ± 36,12 44,97 ± 26,98 43,97 ± 32,96 77,09 ± 57,98 66,47 ± 
49,59(a)
Total proteins (g/dL) 6,4 8,3 7,14 ± 0,51 7,08 ± 0,37 7,00 ± 0,67 7,15 ± 0,32 7,20 ± 0,44 7,00 ± 0,32(a) 7,21 ± 0,36 7,13 ± 0,49
Cholesterol (mg/dL) 190 241,59 ± 52,41 236,03 ± 52,09 223,22 ± 49,28 226,53 ± 34,47 241,47 ± 35,61 224,69 ± 26,44 
(a)
238,25 ± 35,48 226,69 ± 33,52
Triglycerides (mg/dL) 180 105,49 ± 41,12 107,89 ± 51,95 130,28 ± 
140,94
108,63 ± 61,67 100,59 ± 41,99 100,38 ± 40,21 101,81 ± 52,76 116,19 ± 
110,20
HDL-cholesterol (mg/dL) 40 50,11 ± 12,59 54,86 ± 12,58 
(a)
48,84 ± 18,54 55,28 ± 15,43 
(a)
53,13 ± 15,57 54,59 ± 12,94 47,53 ± 14,14 52,69 ± 
14,58(a)
LDL-cholesterol (mg/dL) 115 169,95 ± 47,83 159,11 ± 46,14 
(a)
152,87 ± 45,41 150,90 ± 35,71 167,88 ± 31,09 149,69 ± 24,62 
(a)
169,61 ± 31,09 152,74 ± 
34,18(a)
HDL/LDL 0,32 ± 0,12 0,38 ± 0,15(a) 0,36 ± 0,17 0,40 ± 0,18 (a) 0,33 ± 0,12 0,38 ± 0,12 (a) 0,30 ± 0,10 0,37 0,13 (a)
Bilirubin total (mg/dL) 0,1 1,3 0,43 ± 0,17 0,43 ± 0,17 0,39 ± 0,17 0,40 ± 0,16 0,43 ± 0,18 0,38 ± 0,11 (a) 0,46 ± 0,23 0,51 ± 0,33
SGOT (AST) (U/L) 37 11,27 ± 3,44 13,11 ± 3,03(a) 11,59 ± 4,15 13,44 ± 4,41(a) 10,88 ± 2,88 12,34 ± 3,46 (a) 11,28 ± 3,99 12,72 ± 3,74(a)
SGPT (ALT) (U/L) 38 9,57 ± 4,38 8,00 ± 4,01(a) 9,91 ± 5,29 8,69 ± 4,50 8,75 ± 4,44 8,09 ± 2,91 10,16 ± 5,12 8,56 ± 3,75 (a)
SGOT/SGPT 1,38 ± 0,68 1,99 ± 0,91(a) 1,46 ± 0,75 1,93 ± 0,97(a) 1,55 ± 0,78 1,73 ± 0,78 1,46 ± 0,51 1,71 ± 0,74(a)
GGT (U/L) 57 27,89 ± 19,64 25,27 ± 12,71 31,13 ± 41,16 31,19 ± 46,32 30,75 ± 56,18 34,31 ± 71,67 34,72 ± 44,76 34,88 ± 42,45
Cholinesterase (U/L) 3930 1150
0
7785,5 ± 
1547,5
7517,7 ± 
1582,5
7235,4 ± 
1987,2
7425,44 ± 
1628,08
7356,2 ± 
1668,9
7061,4 ± 1366,8 7178,8 ± 
1320,6
7063,3 ± 
1075,9
Amylase (U/L) 100 57,03 ± 17,15 56,22 ± 15,92 115,81 ± 
317,01
128,16 ± 
372,96
59,13 ± 22,08 58,53 ± 22,46 63,88 ± 21,48 62,66 ± 21,72
Lipase (U/L) 7 60 30,22 ± 15,18 27,35 ± 8,30 32,25 ± 14,01 32,09 ± 12,64 31,00 ± 15,38 29,44 ± 14,72 30,59 ± 13,29 28,19 ± 10,31
Trypsin (μg/L) 10 57 44,23 ± 12,81 46,31 ± 10,56 49,19 ± 12,50 52,21 ± 12,78 44,58 ± 10,36 48,49 ± 18,86 43,86 ± 12,36 45,14 ± 11,74
Sodium (mmol/L) 135 145 139,70 ± 3,65 139,89 ± 5,29 137,03 ± 6,99 140,63 ± 1,90 
(a)
139,75 ± 4,18 140,59 ± 2,56 140,00 ± 2,87 140,63 ± 2,57
Potassium (mmol/L) 3,5 5,1 3,99 ± 0,24 3,97 ± 0,25 3,89 ± 0,36 3,96 ± 0,24 3,86 ± 0,25 3,98 ± 0,21 (a) 3,90 ± 0,22 3,89 ± 0,25
Calcium (mg/L) 86 100 91,81 ± 5,35 92,73 ± 5,89 90,69 ± 9,42 93,69 ± 6,40 93,16 ± 4,01 93,31 ± 4,59 94,50 ± 3,32 93,41 ± 4,32
Phosphorus (mg/dL) 2,7 4,5 3,60 ± 0,44 3,70 ± 0,43 3,53 ± 0,55 3,65 ± 0,46 3,59 ± 0,43 3,70 ± 0,43 3,62 ± 0,40 3,63 ± 0,44
Cupper (μg/dL) 70 155 91,57 ± 14,43 108,19 ± 16,23 
(a)
101,50 ± 35,66 111,44 ± 24,69 
(a)
85, 48 ± 13,75 101,81 ± 16,70 
(a)
93,56 ± 15,15 110,63 ± 14,03 
(a)
Magnesium (mg/dL) 1,6 2,5 2,06 ± 0,14 1,95 ± 0,17(a) 1,98 ± 0,22 1,92 ± 0,17 2,05 ± 0,20 1,92 ± 0,14 (a) 1,99 ± 0,18 1,92 ± 0,18 (a)
Zinc (μg/dL) 50 120 67,59 ± 7,77 75,08 ± 11,00 
(a)
66,19 ± 10,64 72,63 ± 11,96 
(a)
64,50 ± 9,80 68,63 ± 8,17 (a) 63,00 ± 7,34 67,00 ± 9,42
25-OH-vit. D3 (ng/mL) 6,3 46,4 19,26 ± 7,30 25,43 ± 8,03 (a) 17,02 ± 7,21 26,31 ± 5,47(a) 16,76 ± 9,62 25,83 ± 8,40 (a) 18,78 ± 9,63 26,21 ± 6,52 (a)
Baseline biochemical safety parameters in serum and after 12 months treatment with placebo (Ca/vit D) and three different ch-OSA doses (Si + Ca/vit D; Si: 3, 6, 12 mg/day), mean ± SD. LL: Lower limit; 
UL: Upper limit; (a) p < 0.05 versus baseline (two-tailed t-test).Page 5 of 10
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BMC Musculoskeletal Disorders 2008, 9:85 http://www.biomedcentral.com/1471-2474/9/85The primary aim of the present study was to investigate
whether the combined treatment of ch-OSA with calcium
& vitamin D3 (Calcichew/D3 forte) is more efficacious in
changing biochemical indices of bone resorption/forma-
tion compared to calcium & vitamin D3 alone. Three dif-
ferent ch-OSA doses were investigated as no previous data
was available for the optimal/effective ch-OSA dose in
man that was bone active. The study was designed to
detect differences in bone markers of 25% between the ch-
OSA and placebo groups. However, the dropout rate was
higher than expected (26%), decreasing the power of the
study. Considering the smaller expected change in BMD
(1–5%, for existing treatments) after only 12 months of
treatment, we expected at best the study to show a trend
for an effect of ch-OSA on BMD. Indeed, the overall find-
ings of the study suggest a trend for ch-OSA to confer
some additional benefit over Ca & Vit D3 treatment, espe-
cially on markers of (bone) collagen metabolism. Few
studies [34-36] report the influence of Ca/vitamin D3 on
bone markers and show a comparable effect to our sub-
jects treated with placebo.
The major effect of ch-OSA supplementation was on
PINP, a marker of type I collagen synthesis and an early
marker of bone formation. There was a trend for ch-OSA
supplementation to increase PINP synthesis at 12
months, however, the difference was only significant for
the 6 and 12 mg doses and without a clear dose response
effect. There was also a corresponding increase in serum
levels of collagen type I C-terminal telopeptide, a marker
of type I collagen degradation, with these ch-OSA doses;
again, suggesting ch-OSA may affect (bone) collagen
metabolism. In an earlier study of ch-OSA supplementa-
tion in young animals, an increase in collagen concentra-
tion was shown in the skin [28]. Similarly in a more recent
study, oral intake of ch-OSA in humans (10 mg Si/day for
20 weeks) resulted in a significant improvement in skin
microrelief and mechanical properties of the skin [30].
This improvement was suggested to be the result of a
regeneration or de novo synthesis of skin collagen. Previ-
ously, Refitt et al. [27] had reported that physiological
concentrations of OSA stimulates collagen type I synthesis
in human osteoblast-like cells and dermal fibroblasts in
vitro and, to promote osteoblastic differentiation. Further-
more, during the last years, bioactive silica-containing
compounds have been demonstrated to induce collagen
synthesis and apatite formation [37-39]. When gels of
these materials were applied in orthopaedic surgery,
improved healing was demonstrated [40-42]. Orthosilicic
acid is present in dissolutions of bioactive silica and was
suggested to be the active compound responsible for the
biological actions of these preparations. Previously, we
have found (unpublished results) that Si is present in the
form of orthosilicic acid in serum and urine after the
intake of 29Si-labelled ch-OSA in humans. Taken into
account the effect on PINP and CTX-I, we suggest that ch-
OSA supplementation is likely to result in stimulation of
type I collagen metabolism in bone. Such a specific effect
Table 3: Biochemical urinary safety parameters
Normal range Placebo (n = 37) ch-OSA
3 mg Si (n = 33) 6 mg Si (n = 33) 12 mg Si (n = 33)
LL UL Baseline T12 Baseline T12 Baseline T12 Baseline T12
Urine analysis*
Glucose* 0 0 0 1 0 0 0 0
Proteins* 2 0 0 0 1 0 1 2
Ketons* 0 0 0 0 0 0 2 0
Bilirubine* 0 0 0 0 0 0 0 0
Urobilinogene* 0 0 0 0 0 0 0 0
Blood* 1 2 0 0 0 0 0 2
Nitrite* 0 0 0 1 1 0 1 0
Leucocyte esterase* 16 19 9 12 8 6 13 18
pH 4,6 8 6,49 ± 0,90 6,28 ± 0,71 6,08 ± 0,89 5,83 ± 0,51 6,20 ± 0,76 6,36 ± 0,84 6,00 ± 0,65 5,98 ± 0,66
Urea/creatinine 13,5 32 24,15 ± 
7,16
26,41 ± 7,81 24,03 ± 
8,22
24,24 ± 9,48 24,69 ± 
6,01
24,76 ± 
8,32
23,58 ± 
7,08
22,13 ± 
7,34
Creatinine (g/L) 0,60 1,80 0,63 ± 0,36 0,63 ± 0,41 0,63 ± 0,39 0,77 ± 0,45 
(a)
0,50 ± 0,29 0,63 ± 0,42 0,66 ± 0,62 0,76 ± 0,63
Uric acid/creatinine 0,23 0,68 0,49 ± 0,20 0,47 ± 0,20 0,45 ± 0,19 0,39 ± 0,21 0,50 ± 0,21 0,43 ± 0,18 0,48 ± 0,25 0,42 ± 0,21
Sodium/creatinine (mmol/g) 90 200 166,09 ± 
68,78
168,15 ± 
99,21
178,37 ± 
109,89
165,28 ± 
157,62
171,38 ± 
111,23
162,55 ± 
100,52
144,02 ± 
85,53
118,99 ± 
85,45
Potassium/creatinine (mmol/g) 22,7 113,6 78,17 ± 
40,39
66,96 ± 
33,02
67,20 ± 
43,67
54,49 ± 
27,96
73,13 ± 
46,85
66,05 ± 
33,25
66,44 ± 
28,54
57,37 ± 
27,89
Calcium/creatinine (mg/g) 45 273 169,18 ± 
85,86
239,76 ± 
130,58 (a)
195,61 ± 
114,65
268,46 ± 
160,38 (a)
240,19 ± 
136,88
261,81 ± 
135,76
198,32 ± 
101,83
190,55 ± 
113,90
Phosphorus/creatinine 0,36 1,18 0,96 ± 0,31 0,90 ± 0,29 0,96 ± 0,32 0,82 ± 
0,31(a)
0,93 ± 0,29 0,81 ± 0,36 0,99 ± 0,26 0,77 ± 0,26 
(a)
Magnesium/creatinine (mg/g) 64 109 117,32 ± 
51,29
125,79 ± 
44,99
118,73 ± 
57,22
119,54 ± 
50,40
131,46 ± 
46,21
125,54 ± 
54,17
132,52 ± 
65,26
110,76 ± 
69,66
Baseline urinary biochemical safety parameters and after 12 months treatment with placebo (Ca/vit D) and three different ch-OSA doses (Si + Ca/vit D; Si: 3, 6, 12 mg/day), 
mean ± SD. LL: Lower limit; UL: Upper limit; * number of patients with parameter present in urine; (a) p < 0.05 versus baseline (two-tailed t-test).Page 6 of 10
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BMC Musculoskeletal Disorders 2008, 9:85 http://www.biomedcentral.com/1471-2474/9/85of ch-OSA on bone collagen metabolism without increas-
ing the synthesis of non-collagenous proteins would
explain why no clear effect was found on osteocalcin and
BAP levels.
Bone strength depends not only on the quantity of bone
mineral (BMD) but also on the quality, which is charac-
terized by several factors including collagen content (and
quality). Collagen provides elasticity and structure in all
connective tissues and several studies have indicated that
collagen is important for bone toughness [43-45] whereas
the mineral component is mainly involved in providing
stiffness. Wang et al. [46] demonstrated that the mechan-
ical integrity of collagen fibres deteriorates with ageing in
human cortical bones and is associated with a higher frac-
ture risk. When the collagen network becomes weaker
with age, it will result in decreased toughness, possibly
due to a reduction in natural cross-links or silicon content.
It has previously been suggested that Si may be an integral
(structural) component of connective tissues as high lev-
els of non-dialysable Si has been reported in connective
tissues and their components suggesting strong (covalent)
associations [47]. Thus ch-OSA supplementation may
improve the mechanical properties of osteopenic bone by
increasing collagen content or improving its quality, how-
ever, this was not investigated here.
BMD at the lumbar spine did not change significantly
with ch-OSA supplementation, but post-hoc subgroup
analysis (subjects with baseline T-score at the femur < -1)
showed a significant change in femoral neck BMD with
the 6 mg dose compared to placebo (Table 5). After 12
months of combined ch-OSA and Ca/vit D treatment,
BMD at the total femur and femoral neck were respec-
tively 0.98% and 2% higher, compared to Ca/vit D alone
(placebo group, Table 5). Our study was not designed to
assess the effect of ch-OSA on fracture risk, but the
increase in femoral BMD may lead to a reduction in the
hip fracture risk.
It is unclear why the association between Si intake and
lumbar spine BMD is weaker compared with the hip sites,
which is the opposite to most trials. This lack of associa-
tion with lumbar spine could be due to a combination of
two factors. Firstly, the insensitivity, or error associated in,
measuring spine BMD by DEXA and the reduced power of
this study to detect small changes in BMD. In addition,
the lumbar spine is the site of artifactual calcification such
as degenerative spine changes and vascular calcification,
and these could mask and thus weaken the association
between Si intake and BMD. Previously, Calomme et al.
reported that ch-OSA supplementation partially, but sig-
nificantly ameliorated the decrease in femoral density in
ovariectomized-aged rats, whereas the effect at the lumbar
spine did not reach significance [31].
The dose of ch-OSA used in this study (3–12 mg Si/day)
was low compared to typical daily intake of Si in Western
populations (20–50 mg; Pennington [48]). Recently
McNaughton et al. [32] reported that mean dietary silicon
intake is 18.3 mg in post-menopausal women aged 60–64
years. The mean age of our subjects in this study was 60.7
years and 85% were post-menopausal. Therefore, the
three different doses in the present study, 3, 6 and 12 mg
Si would typically increase daily dietary Si intakes by 16.4,
33 and 66% respectively, although this has not taken into
account relative Si bioavailability of the diet. Previous
comparison studies have shown that ch-OSA has high
bioavailability compared to other silicon compounds/
supplements such as colloidal silicic acid and phytolytic
silica [49,50]. The major dietary sources of Si are cereal/
whole grain based products and some vegetables and
fruits, but modern food processing, including refining,
reduces the Si content of the foods and thus dietary Si
intakes. Jugdaohsingh et al. [24] reported a significant,
positive correlation between dietary silicon intake and
BMD at all hip sites in men and pre-menopausal women,
suggesting that increased silicon intake is associated with
increased cortical BMD in these populations.
Table 4: Bone formation and resorption markers
Placebo ch-OSA
3 mg Si 6 mg Si 12 mg Si
Baseline 6 months 12 months Baseline 6 months 12 months Baseline 6 months 12 months Baseline 6 months 12 months
serum OC (ng/mL) 9.74 ± 
3.16
9.11 ± 
3.73a
7.86 ± 
2.26a
10.17 ± 
3.91
9.11 ± 
3.02a
8.33 ± 
2.63a
10.65 ± 
3.32
9.74 ± 
3.05a
9.08 ± 
2.56a
10.16 ± 
3.67
9.43 ± 
3.02a
8.79 ± 
2.82a
serum BAP (U/L) 21.65 ± 
6.30
18.91 ± 
5.56
18.61 ± 
5.56
20.43 ± 
7.24
19.61 ± 
6.66
18.97 ± 
5.98
21.85 ± 
6.31
20.59 ± 
6.39
20.16 ± 
6.01
21.58 ± 
7.36
20.19 ± 
5.62
19.75 ± 
5.96
serum PINP (μg/L) 47.20 ± 
13.45
40.83 ± 
14.05a
36.49 ± 
12.04a
46.28 ± 
21.46
40.27 ± 
20.18a
35.63 ± 
12.34a
44.78 ± 
16.07
38.60 ± 
13.35a
42.04 ± 
12.77a,1,2
48.77 ± 
15.09
42.87 ± 
11.89a,2
43.73 ± 
12.11a,1,2
serum DPD (/Cr) 5.57 ± 
3.12
4.77 ± 
1.12
4.74 ± 
1.28
5.22 ± 
1.50
5.17 ± 
2.04
4.83 ± 
1.62
5.74 ± 
1.45
5.81 ± 
1.68
5.49 ± 
1.70
5.92 ± 
1.57
5.36 ± 
1.91
6.22 ± 
2.62
serum CTX-I (μg/mmol Cr) 359.01 ± 
129.89
271.15 ± 
124.21
284.66 ± 
134.09
331.88 ± 
155.87
245.03 ± 
107.82
220.71 ± 
98.08
349.10 ± 
126.71
294.21 ± 
137.802
319.38 ± 
160.782
360.43 ± 
139.00
310.95 ± 
122.052
320.99 ± 
113.632
Bone formation and resorption markers at baseline (mean ± SD) and after 6 and 12 months supplementation with placebo (Ca/vit D) and three different ch-OSA doses (Si + Ca/vit D; Si: 3, 6, 12 mg/day). 
a: p < 0.05 (MANCOVA, vs. baseline), 1: p < 0.05 (MANCOVA, vs. placebo) and 2: p < 0.05 (MANCOVA, vs. 3 mg Si).
OC: osteocalcin, BAP: bone specific alkaline phosphatase, PINP: procollagen type I N-terminal propeptide, DPD: deoxypyridinoline, CTX-I: C-terminal collagen type I.Page 7 of 10
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BMC Musculoskeletal Disorders 2008, 9:85 http://www.biomedcentral.com/1471-2474/9/85Of the 184 women randomised into the study, only 136
completed the study. Reasons for withdrawal were unfore-
seen illness/medical conditions and some volunteers
deciding not to take any further part in the study (non-
medical). There were no ch-OSA related adverse events
observed during this trial and biochemical safety parame-
ters remained within the normal range. Consequently,
Table 5: Change in bone mineral density
Placebo (n = 20) ch-OSA
3 mg Si (n = 18) 6 mg Si (n = 19) 12 mg Si (n = 24)
Spine total 0.58 ± 2 0.08 ± 3 0.24 ± 2 0.11 ± 3
Femur total -0.54 ± 2 0.07 ± 3 0.44 ± 3 0.04 ± 3
Femur neck -1.22 ± 3 -1.58 ± 3 0.78 ± 3a,b -0.84 ± 2c
Relative % change in bone mineral density compared to baseline (mean ± SD), after 12 months supplementation with placebo (Ca/vit D) and three 
different ch-OSA doses (Si + Ca/vit D; Si: 3, 6, 12 mg/day), in a subgroup of patients with documented osteopenia at the femur. a: p < 0.05 versus 
placebo, b: p < 0.05 (t-test) versus 3 mg Si and c: p < 0.05 versus 6 mg Si (t-test).
Change in bone formation markersFigur 1
Change in bone formation markers. Relative change (mean ± SE, %) in bone formation markers PINP, BAP and OC com-
pared to baseline after 6 and 12 months supplementation with placebo (Ca/vit D) and three different ch-OSA doses (Si + Ca/
vit D; Si: 3, 6, 12 mg/day). a: p < 0.05 (t-test) versus placebo; b: p < 0.05 (t-test) versus 3 mg Si.
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BMC Musculoskeletal Disorders 2008, 9:85 http://www.biomedcentral.com/1471-2474/9/85oral use of ch-OSA, up to 12 mg Si daily for 12 months,
can be regarded as safe.
Total cholesterol and LDL-cholesterol were already
increased at baseline, which is most likely due to the con-
sumption of a diet high in cholesterol and saturated fats
[51]. Baseline urinary values of magnesium/creatinine
ratio were higher than the upper limit of the normal range
in all four treatment groups possibly due to a lower mus-
cle mass in osteopenic women compared to healthy sub-
jects [52].
Compliance was comparable for the three dosing groups
although the variation was considerable higher for the
lowest dose (3 mg). Considering, the galenic form (liq-
uid) this was not unexpected as dosing of drops can be
inaccurate, especially in case of low volumes. Therefore
solid galenic formulations of ch-OSA may be more prefer-
able.
Finally, choline, the stabilizing agent in ch-OSA might act
synergistically with orthosilicic acid on bone. In fact,
choline is classified by the Food and Nutrition Board as an
essential nutrient. Although humans can synthesize
choline in small amounts, dietary sources are needed to
prevent deficiency [53]. Choline is a precursor of phos-
pholipids, which are essential components of biological
membranes, and is involved in cell signaling and lipid
transport/metabolism. Choline was previously reported
to minimize leg weakness in broiler chicks [54]. Supple-
mental choline chloride significantly increased the hex-
osamine content of the epiphyseal cartilage as compared
to cartilage from chicks fed the basal diet. Dietary choline
deficiency in rats led to a marked reduction in osteogene-
sis [55]. Microscopic observation revealed that osteogene-
sis was lower in rats fed a choline-deficient diet, at both 15
and 30 days, and that this decrease did not revert with a
control diet. Histomorphometric evaluation showed 37%
and 27% reduction in bone tissue density at 5 and 30
days, respectively, and a 30% decrease in bone formation
at 30 days, compared to controls. It is therefore possible
that the effect on bone of relatively low doses ch-OSA
(compared to the dietary Si intake), observed in the
present study, could be in part explained by a synergistic
action of orthosilicic acid and choline.
Conclusion
Accumulated evidence over the last 30 years has suggested
a role for Si in bone and connective tissue health. The
study presented here suggests that the combined treat-
ment of ch-OSA (Si) with Ca/Vit D3 is safe and has a
potentially beneficial effect on bone turnover, especially
on bone collagen, and possibly also on femoral BMD
compared to Ca/Vit D3 alone. Studies in a larger number
of subjects are needed to investigate further the effect of
ch-OSA on BMD and its impact on fracture incidence.
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